AZD0516
AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer[1].
Product Specifications
UNSPSC
12352211
Target
Antibody-Drug Conjugates (ADCs) ; Topoisomerase
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
95.82
Smiles
[AZD0516]
References & Citations
[1]1158-Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer. AACR Annual Meeting 2025 Itinerary Planner Home.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
37101151 3x 1.0 µg DNA
PNMA3 CRISPR All-in-one AAV vector set (with saCas9)(Human)
Sign In for Pricing
View Details MBS6138867-01 0.1 mL
RSU1 (Ras Suppressor Protein 1, RSP-1, Rsu-1, RSP1) APC
Sign In for Pricing
View Details MBS6138867-02 5x 0.1 mL
RSU1 (Ras Suppressor Protein 1, RSP-1, Rsu-1, RSP1) APC
Sign In for Pricing
View Details